Meropenem Dosing and Duration for Klebsiella Infections
For susceptible Klebsiella infections, use meropenem 1 gram IV every 8 hours infused over 3 hours for 7-14 days depending on infection site, with dose adjustments required for renal impairment. 1
Standard Dosing by Infection Type
Bloodstream Infections
- Dose: 1 gram IV every 8 hours
- Duration: 7-14 days 2
- Infusion: Extended 3-hour infusion preferred over standard 30-minute infusion for better target attainment 3, 4
Complicated Intra-Abdominal Infections
- Dose: 1 gram IV every 8 hours 1
- Duration: 5-10 days 2
- Note: Duration should be individualized based on source control adequacy and clinical response 2
Complicated Urinary Tract Infections
- Dose: 1 gram IV every 8 hours
- Duration: 5-10 days 2
Hospital-Acquired/Ventilator-Associated Pneumonia
Renal Dose Adjustments
Critical consideration: Meropenem is renally eliminated and requires dose adjustment based on creatinine clearance 1, 6:
| CrCl (mL/min) | Dose | Interval |
|---|---|---|
| >50 | 1 gram | Every 8 hours |
| 26-50 | 1 gram | Every 12 hours |
| 10-25 | 500 mg | Every 12 hours |
| <10 | 500 mg | Every 24 hours |
For hemodialysis patients: Administer dose after each dialysis session, as hemodialysis significantly removes meropenem (half-life reduced from 7.0 to 2.9 hours during dialysis) 6.
For CRRT patients: 0.5-1 gram every 6-8 hours as 3-hour infusion, depending on residual renal function (CrCl 10-50 mL/min) 7.
Special Considerations for Carbapenem-Resistant Klebsiella
For Carbapenem-Resistant Enterobacterales (CRE)
If dealing with carbapenem-resistant Klebsiella pneumoniae (CRKP), meropenem can still be used in specific circumstances:
- High-dose extended infusion: 1-2 grams IV every 8 hours as 3-hour infusion when MIC ≤8 mg/L 2, 8
- Combination therapy preferred: Meropenem combined with colistin or tigecycline for CRE bloodstream infections 2
- MIC considerations: Extended infusion of 3 hours is suggested if meropenem MIC ≥8 mg/L 2
Important caveat: For KPC-producing Klebsiella with MIC 8-32 mg/L, high-dose meropenem (up to 6-8 g/day) by continuous or extended infusion may achieve adequate exposure in patients with reduced renal clearance, but therapeutic drug monitoring (TDM) is strongly recommended 3, 9.
Augmented Renal Clearance
Critical pitfall: Patients with normal or augmented renal clearance (CrCl ≥90 mL/min) often fail to achieve adequate meropenem concentrations with standard dosing 9, 4.
For CrCl ≥90 mL/min:
- Increase to 2 grams every 8 hours as 3-hour infusion, OR
- Consider continuous infusion (3-6 grams/day) 9, 4
Infusion Strategy
Extended infusion (3 hours) is superior to standard 30-minute infusion for achieving pharmacodynamic targets, particularly for pathogens with higher MICs 3, 10, 4:
- Standard 30-minute infusion: 49.5% probability of target attainment
- Continuous infusion: 95.3% probability of target attainment 4
The pharmacodynamic target for meropenem is maintaining plasma concentration above the MIC for 100% of the dosing interval (100% fT>MIC), which is best achieved with extended or continuous infusion 3, 9.
Therapeutic Drug Monitoring
TDM is recommended when:
- Treating infections with MIC ≥8 mg/L 11
- Patients have augmented renal clearance 9
- Using high-dose regimens (>6 g/day) 3
- Target trough concentration: avoid levels >100 mg/L to minimize neurotoxicity risk 3
Common Pitfalls
- Underdosing in augmented renal clearance: Standard doses fail in critically ill patients with CrCl >90 mL/min 9, 4
- Short infusion times: 30-minute infusions are suboptimal; use 3-hour extended infusions 3, 10, 4
- Ignoring MIC values: For MIC >4 mg/L, standard dosing is inadequate 3, 10
- Failure to adjust for renal function: Both impairment and augmentation require dose modification 1, 9